https://www.pharmaradar360.com/article/sellas-life-sciences-clinical-biopharmaceutical-company-fcf83941c46d3fc8Pharma Surgeen2026-07-30T10:32:04.000ZSELLAS Life Sciences - Clinical Biopharmaceutical Companyhttps://www.pharmaradar360.com/article/when-foreign-investments-in-pharma-and-biotech-become-a-national-security-concer-f26386bda2965018Pharma Surgeen2026-07-30T10:06:55.000ZWhen Foreign Investments in Pharma and Biotech Become a National Security Concernhttps://www.pharmaradar360.com/article/takeda-pharmaceutical-nyse-tak-q1-2026-revenue-1-22t-eps-71-65-2bee652264979825Pharma Surgeen2026-07-30T10:05:10.000ZTakeda Pharmaceutical (NYSE: TAK) Q1 2026 revenue ¥1.22T, EPS ¥71.65https://www.pharmaradar360.com/article/sharp-rise-in-cyclospora-infections-linked-to-mexico-travel-6e286df30d5ba91bPharma Surgeen2026-07-30T10:00:00.000ZSharp rise in cyclospora infections linked to Mexico travelhttps://www.pharmaradar360.com/article/amneal-reports-second-quarter-2026-financial-results-af07df3365c7afc1Pharma Surgeen2026-07-30T10:00:00.000ZAmneal Reports Second Quarter 2026 Financial Resultshttps://www.pharmaradar360.com/article/181-294-shares-in-teva-pharmaceutical-industries-ltd-teva-acquired-by-healthcare-d7284f5efdf23c9ePharma Surgeen2026-07-30T09:46:11.000Z181,294 Shares in Teva Pharmaceutical Industries Ltd. $TEVA Acquired by Healthcare of Ontario Pension Plan Trust Fundhttps://www.pharmaradar360.com/article/ono-pharmaceutical-partners-with-phylo-to-embed-agentic-ai-with-every-discovery-5e1561178cecd539Pharma Surgeen2026-07-30T09:32:41.000ZOno Pharmaceutical partners with Phylo to embed agentic AI with every discovery scientisthttps://www.pharmaradar360.com/article/in-photos-sudents-in-maharashtra-may-soon-see-healthier-school-menus-7dcdc96aed7a0d00Pharma Surgeen2026-07-30T09:30:00.000ZIN PHOTOS: Sudents in Maharashtra may soon see healthier school menushttps://www.pharmaradar360.com/article/j-j-pays-sail-785m-charting-course-to-possible-in-vivo-car-t-buyout-7e8cdec0ea5682d4Pharma Surgeen2026-07-30T09:29:11.000ZJ&J pays Sail $785M, charting course to possible in vivo CAR-T buyouthttps://www.pharmaradar360.com/article/study-protecting-tropical-forests-could-save-pharmaceutical-industry-up-to-1-2tr-2a97d26f780a7f2aPharma Surgeen2026-07-30T09:20:58.000ZStudy: Protecting tropical forests could save pharmaceutical industry up to $1.2trhttps://www.pharmaradar360.com/article/mumbai-food-safety-crackdown-every-licence-suspended-since-tukaram-mundhe-took-c-6bff75affeb8d749Pharma Surgeen2026-07-30T09:20:00.000ZMumbai food safety crackdown: Every licence suspended since Tukaram Mundhe took charge as FDA chiefhttps://www.pharmaradar360.com/article/ukhsa-report-shows-2-877-excess-deaths-caused-by-may-and-june-heatwaves-87b94de79fef5d1ePharma Surgeen2026-07-30T09:08:34.000ZUKHSA report shows 2,877 excess deaths caused by May and June heatwaveshttps://www.pharmaradar360.com/article/respiratory-syncytial-virus-rsv-vaccination-for-older-adults-b709407e14b34df9Pharma Surgeen2026-07-30T09:01:25.000ZRespiratory syncytial virus (RSV): vaccination for older adultshttps://www.pharmaradar360.com/article/using-the-professional-title-nurse-17092dc6e135d308Pharma Surgeen2026-07-30T09:00:05.000ZUsing the professional title ‘nurse’https://www.pharmaradar360.com/article/respiratory-syncytial-virus-rsv-vaccination-programme-7a9417a4fdf76e56Pharma Surgeen2026-07-30T08:58:55.000ZRespiratory syncytial virus (RSV) vaccination programmehttps://www.pharmaradar360.com/article/maharashtra-fda-staff-allege-double-shifts-severe-work-pressure-amid-staff-short-86956cd7872be855Pharma Surgeen2026-07-30T08:39:43.000ZMaharashtra FDA Staff Allege Double Shifts, Severe Work Pressure Amid Staff Shortagehttps://www.pharmaradar360.com/article/principal-financial-group-inc-decreases-holdings-in-teva-pharmaceutical-industri-f0c7609b279ab669Pharma Surgeen2026-07-30T08:37:43.000ZPrincipal Financial Group Inc. Decreases Holdings in Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/teva-pharmaceutical-industries-teva-raises-revenue-guidance-is-the-15-undervalua-2edba534d77c89a2Pharma Surgeen2026-07-30T08:36:25.000ZTeva Pharmaceutical Industries (TEVA) Raises Revenue Guidance, Is The 15% Undervaluation Still There?https://www.pharmaradar360.com/article/some-more-notes-on-pharmaceutical-tariffs-b506994e46719a39Pharma Surgeen2026-07-30T08:35:00.000ZSome More Notes On Pharmaceutical Tariffshttps://www.pharmaradar360.com/article/u-s-dependence-on-china-is-a-national-security-risk-bdad282a651ec92fPharma Surgeen2026-07-30T08:30:25.000ZU.S. dependence on China is a national security riskhttps://www.pharmaradar360.com/article/environmental-monitoring-following-the-grenfell-tower-fire-85d5cc3f2b36adbcPharma Surgeen2026-07-30T08:30:21.000ZEnvironmental monitoring following the Grenfell Tower firehttps://www.pharmaradar360.com/article/national-norovirus-and-rotavirus-surveillance-reports-2026-to-2027-season-1cc078fa257f8153Pharma Surgeen2026-07-30T08:30:16.000ZNational norovirus and rotavirus surveillance reports: 2026 to 2027 seasonhttps://www.pharmaradar360.com/article/ukhsa-ad-hoc-statistical-publications-3cbe759f572dbfdcPharma Surgeen2026-07-30T08:30:15.000ZUKHSA ad hoc statistical publicationshttps://www.pharmaradar360.com/article/interim-heat-mortality-monitoring-report-england-may-and-june-2026-a051d1a7af9c587cPharma Surgeen2026-07-30T08:30:14.000ZInterim heat mortality monitoring report, England: May and June 2026https://www.pharmaradar360.com/article/pre-release-access-lists-tuberculosis-in-england-national-quarterly-reports-8f126ee050dac709Pharma Surgeen2026-07-30T08:30:13.000ZPre-release access lists: Tuberculosis in England national quarterly reportshttps://www.pharmaradar360.com/article/pre-release-access-list-reports-of-cases-of-tb-to-uk-enhanced-tuberculosis-surve-f8f3de78c8bebefaPharma Surgeen2026-07-30T08:30:13.000ZPre-release access list: Reports of cases of TB to UK enhanced tuberculosis surveillance systems 2000 to 2024https://www.pharmaradar360.com/article/measles-mumps-and-rubella-lab-confirmed-cases-in-england-2026-1bfcb2c59c9cd8a7Pharma Surgeen2026-07-30T08:30:13.000ZMeasles, mumps and rubella: lab-confirmed cases in England 2026https://www.pharmaradar360.com/article/health-protection-report-volume-20-2026-f9e0b8a49f9df3c3Pharma Surgeen2026-07-30T08:30:13.000ZHealth Protection Report volume 20 (2026)https://www.pharmaradar360.com/article/haemophilus-influenzae-lab-reports-by-age-group-and-serotype-99bef29f7847333aPharma Surgeen2026-07-30T08:30:13.000ZHaemophilus influenzae: lab reports by age group and serotypehttps://www.pharmaradar360.com/article/tuberculosis-in-england-national-quarterly-reports-8174ab5932d8ff62Pharma Surgeen2026-07-30T08:30:09.000ZTuberculosis in England: national quarterly reportshttps://www.pharmaradar360.com/article/reports-of-cases-of-tb-to-uk-enhanced-tuberculosis-surveillance-systems-2000-to-df1cab884cded473Pharma Surgeen2026-07-30T08:30:09.000ZReports of cases of TB to UK enhanced tuberculosis surveillance systems, 2000 to 2025https://www.pharmaradar360.com/article/reports-of-cases-of-tb-to-uk-enhanced-tuberculosis-surveillance-systems-2000-to-8d544b87c4e3a12aPharma Surgeen2026-07-30T08:30:09.000ZReports of cases of TB to UK enhanced tuberculosis surveillance systems: 2000 to 2024https://www.pharmaradar360.com/article/mycoplasma-genitalium-antimicrobial-resistance-surveillance-mars-8b728d0038ccd66fPharma Surgeen2026-07-30T08:30:09.000ZMycoplasma genitalium antimicrobial resistance surveillance (MARS)https://www.pharmaradar360.com/article/tuberculosis-tb-diagnosis-screening-management-and-data-ace9722645b7304dPharma Surgeen2026-07-30T08:30:09.000ZTuberculosis (TB): diagnosis, screening, management and datahttps://www.pharmaradar360.com/article/pertussis-immunisation-in-pregnancy-vaccine-coverage-england-d2e1f6887adda4f0Pharma Surgeen2026-07-30T08:30:08.000ZPertussis immunisation in pregnancy: vaccine coverage (England)https://www.pharmaradar360.com/article/chong-kun-dang-bio-gains-fda-trial-approval-f1a3e487dc1718cePharma Surgeen2026-07-30T08:23:45.000ZChong Kun Dang Bio Gains FDA Trial Approvalhttps://www.pharmaradar360.com/article/transparency-data-mhra-performance-data-cf9e28d146e3c0ecPharma Surgeen2026-07-30T08:21:25.000ZTransparency data: MHRA Performance Datahttps://www.pharmaradar360.com/article/decision-marketing-authorisations-granted-in-2026-62e98adcc67319b8Pharma Surgeen2026-07-30T08:19:39.000ZDecision: Marketing authorisations Granted in 2026https://www.pharmaradar360.com/article/decision-parallel-import-licences-granted-in-2026-055d0ff39f0aca89Pharma Surgeen2026-07-30T08:19:35.000ZDecision: Parallel import licences granted in 2026https://www.pharmaradar360.com/article/masschallenge-launches-breakthrough-bio-to-catapult-international-biotech-and-me-60ae51b773c0c700Pharma Surgeen2026-07-30T08:11:01.000ZMassChallenge Launches Breakthrough Bio to Catapult International Biotech and Medtech Start-ups in the US Markethttps://www.pharmaradar360.com/article/krystal-biotech-krys-could-be-40-overvalued-as-kb801-news-tests-its-price-ced2ebb44249f5dfPharma Surgeen2026-07-30T08:07:55.000ZKrystal Biotech (KRYS) Could Be 40% Overvalued As KB801 News Tests Its Pricehttps://www.pharmaradar360.com/article/takeda-pharmaceutical-profit-drops-9-in-fiscal-q1-0b40fe1c3b94f101Pharma Surgeen2026-07-30T08:01:39.000ZTakeda Pharmaceutical Profit Drops 9% in Fiscal Q1https://www.pharmaradar360.com/article/takeda-pharmaceutical-fiscal-q1-core-earnings-revenue-rise-a17535fb7bcb9187Pharma Surgeen2026-07-30T07:46:40.000ZTakeda Pharmaceutical Fiscal Q1 Core Earnings, Revenue Risehttps://www.pharmaradar360.com/article/takeda-pharmaceutical-company-limited-reaffirms-earnings-guidance-for-the-fiscal-8055febee8b73041Pharma Surgeen2026-07-30T07:35:42.000ZTakeda Pharmaceutical Company Limited Reaffirms Earnings Guidance for the Fiscal Year 2026https://www.pharmaradar360.com/article/pune-fda-suspends-licences-of-21-food-establishments-seizes-50-65-lakh-worth-of-83f8e265a470d0d3Pharma Surgeen2026-07-30T07:34:06.000ZPune: FDA Suspends Licences Of 21 Food Establishments, Seizes ₹50.65 Lakh Worth Of Suspected Adulteratedhttps://www.pharmaradar360.com/article/a-maternal-gbs-vaccine-just-cleared-phase-1-2-here-s-what-the-trial-design-tells-ae32d90cf0700456Pharma Surgeen2026-07-30T07:32:08.000ZA Maternal GBS Vaccine Just Cleared Phase 1/2. Here’s What the Trial Design Tells Us About the Regulatory Gauntlet Ahead.https://www.pharmaradar360.com/article/guidance-london-region-i-mhra-regulatory-sandbox-call-for-expressions-of-interes-8d6286a59cfad7e3Pharma Surgeen2026-07-30T07:28:53.000ZGuidance: London Region I MHRA Regulatory Sandbox: call for expressions of interesthttps://www.pharmaradar360.com/article/workwell-1415ead5314a3eeaPharma Surgeen2026-07-30T07:24:00.000ZWorkWellhttps://www.pharmaradar360.com/article/benzodiazepines-en-aanverwante-geneesmiddelen-herhaling-van-de-aanbevelingen-voo-2f8e2bd794554a15Pharma Surgeen2026-07-30T07:22:52.000ZBenzodiazepines en aanverwante geneesmiddelen: herhaling van de aanbevelingen voor een rationeel gebruikhttps://www.pharmaradar360.com/article/does-biomarin-bmrn-expanding-into-renu-syndrome-refine-its-rare-disease-pipeline-bc1c8a4f8f049d63Pharma Surgeen2026-07-30T07:15:07.000ZDoes BioMarin (BMRN) Expanding Into ReNU Syndrome Refine Its Rare Disease Pipeline Strategy?https://www.pharmaradar360.com/article/takeda-pharmaceutical-4502-earnings-strong-1q-beats-estimates-with-net-income-at-9591ff56eb0a2577Pharma Surgeen2026-07-30T06:50:49.000ZTakeda Pharmaceutical (4502) Earnings: Strong 1Q Beats Estimates with Net Income at 113.2 Billion Yenhttps://www.pharmaradar360.com/article/double-shifts-work-pressure-maharashtra-food-safety-body-head-faces-staff-shorta-d11ce877ca9cd2b8Pharma Surgeen2026-07-30T06:47:06.000Z'Double Shifts, Work Pressure': Maharashtra Food Safety Body Head Faces 'Staff Shortage' Complainthttps://www.pharmaradar360.com/article/viking-therapeutics-advances-vk2735-oral-program-into-phase-3-trials-aa8acd481d3712d6Pharma Surgeen2026-07-30T06:36:50.000ZViking Therapeutics Advances VK2735 Oral Program Into Phase 3 Trialshttps://www.pharmaradar360.com/article/beijing-hanmi-profit-nearly-vanishes-amid-receivables-concerns-885bfdde94dad1f2Pharma Surgeen2026-07-30T06:23:14.000ZBeijing Hanmi Profit Nearly Vanishes Amid Receivables Concernshttps://www.pharmaradar360.com/article/150426-lolota-professional-nails-uv-uv-led-gel-polish-46-eb03349d5e4bea4aPharma Surgeen2026-07-30T06:19:52.000ZΑνάκληση της παρτίδας 150426 του Καλλυντικού προϊόντος Lolota Professional nails UV& UV LED GEL POLISH 46https://www.pharmaradar360.com/article/gsk-strikes-ai-deal-with-uk-biotech-to-boost-early-pipeline-8d7b821518d58eb4Pharma Surgeen2026-07-30T06:00:00.000ZGSK Strikes AI Deal With UK Biotech to Boost Early Pipelinehttps://www.pharmaradar360.com/article/the-top-5-analyst-questions-from-thermo-fisher-s-q2-earnings-call-b079b99314c28b34Pharma Surgeen2026-07-30T05:43:00.000ZThe Top 5 Analyst Questions From Thermo Fisher’s Q2 Earnings Callhttps://www.pharmaradar360.com/article/seize-the-golden-window-for-biotech-ipos-attovia-aims-to-raise-up-to-212-5-milli-8ac8d1fbd092cdd9Pharma Surgeen2026-07-30T05:37:58.000ZSeize the Golden Window for Biotech IPOs, Attovia Aims to Raise Up to $212.5 Million in Nasdaq Debuthttps://www.pharmaradar360.com/article/excellent-growth-and-progress-in-h1-2026-ef864d88f3d12173Pharma Surgeen2026-07-30T05:16:12.000ZExcellent growth and progress in H1 2026https://www.pharmaradar360.com/article/bombay-high-court-seeks-inspection-details-of-government-canteens-amid-fda-enfor-5b63108acf7cf3fdPharma Surgeen2026-07-30T05:15:56.000ZBombay High Court Seeks Inspection Details of Government Canteens Amid FDA Enforcement Drivehttps://www.pharmaradar360.com/article/cspc-hunan-jingfeng-pharmaceutical-co-ltd-class-a-revenue-breakdown-szse-000908-42176037344361caPharma Surgeen2026-07-30T05:10:48.000ZCSPC Hunan Jingfeng Pharmaceutical Co Ltd Class A Revenue Breakdown – SZSE:000908https://www.pharmaradar360.com/article/conserving-tropical-forests-could-preserve-billions-of-dollars-in-pharmaceutical-623f935b271ac85cPharma Surgeen2026-07-30T05:02:55.000ZConserving tropical forests could preserve billions of dollars in pharmaceutical value from undiscovered drugshttps://www.pharmaradar360.com/article/bombay-hc-asks-maharashtra-govt-to-give-details-of-fda-inspections-at-state-run-00d8a60d95ac026fPharma Surgeen2026-07-30T05:01:04.000ZBombay HC asks Maharashtra govt. to give details of FDA inspections at State-run canteens, eating placeshttps://www.pharmaradar360.com/article/daewoong-s-botulinum-toxin-nabota-enters-kuwait-796978f06b04efc8Pharma Surgeen2026-07-30T04:50:15.000ZDaewoong's botulinum toxin Nabota enters Kuwaithttps://www.pharmaradar360.com/article/the-lancet-bloodstream-delivered-cell-therapy-slows-muscle-decline-in-1423241d925dedd0Pharma Surgeen2026-07-30T04:01:40.000ZThe Lancet: Bloodstream-delivered cell therapy slows muscle decline inhttps://www.pharmaradar360.com/article/the-results-suggest-the-potential-usefulness-of-s-equol-in-women-with-severe-sym-54ff3192e96597eaPharma Surgeen2026-07-30T04:00:00.000ZThe Results Suggest the Potential Usefulness of S-Equol in Women with Severe Symptoms of PMS and PMDD New Findings Contribute to Advancing Support for Women's Healthhttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-honz-pharmaceutical-co-ltd-class-a-szse-30-8e1b3cdef3ff6611Pharma Surgeen2026-07-30T03:36:08.000ZEnterprise value to EBITDA forward of Honz Pharmaceutical Co., Ltd. Class A – SZSE:300086https://www.pharmaradar360.com/article/families-gather-at-state-capitol-to-mark-prescribed-harm-awareness-day-70bfdd52cd81d003Pharma Surgeen2026-07-30T03:25:00.000ZFamilies gather at state capitol to mark Prescribed Harm Awareness Dayhttps://www.pharmaradar360.com/article/asca2026-last-chance-to-get-early-bird-discount-4eba3a77cedaa463Pharma Surgeen2026-07-30T02:43:53.000ZASCA2026: Last Chance to Get Early Bird Discounthttps://www.pharmaradar360.com/article/12-funding-rounds-that-show-where-apac-biotech-capital-is-going-ca8fd3e7804f69f6Pharma Surgeen2026-07-30T02:26:32.000Z12 Funding Rounds That Show Where APAC Biotech Capital Is Goinghttps://www.pharmaradar360.com/article/veraxa-biotech-nasdaq-vrxa-expands-patent-portfolio-to-support-next-generation-c-dc049ad67e7e53e2Pharma Surgeen2026-07-30T01:55:47.000ZVERAXA Biotech (NASDAQ: VRXA) Expands Patent Portfolio to Support Next-Generation Cancer Therapy Platformshttps://www.pharmaradar360.com/article/dimerix-asx-dxb-builds-pipeline-momentum-with-phase-3-progress-and-new-commercia-c362f2bb116cbf0ePharma Surgeen2026-07-30T01:53:00.000ZDimerix (ASX:DXB) Builds Pipeline Momentum With Phase 3 Progress and New Commercial Partnershiphttps://www.pharmaradar360.com/article/alterity-therapeutics-asx-ath-gains-ground-as-fda-clears-pathway-toward-ath434-p-57be5a1ea08d056dPharma Surgeen2026-07-30T01:34:00.000ZAlterity Therapeutics (ASX:ATH) Gains Ground as FDA Clears Pathway Toward ATH434 Phase 3 Trialhttps://www.pharmaradar360.com/article/precision-trading-with-fortress-biotech-inc-9-375-series-a-cumulative-redeemable-e3c394a5c6571806Pharma Surgeen2026-07-30T01:10:01.000ZPrecision Trading with Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP) Risk Zoneshttps://www.pharmaradar360.com/article/k-cab-eyes-fda-approval-after-dominating-home-market-expanding-abroad-673b1dadcb993ed5Pharma Surgeen2026-07-30T00:40:38.000ZK-CAB eyes FDA approval after dominating home market, expanding abroadhttps://www.pharmaradar360.com/article/krystal-biotech-krys-is-up-7-9-after-s-p-400-move-and-new-kb801-patent-filing-up-245c39255f31ed89Pharma Surgeen2026-07-30T00:15:00.000ZKrystal Biotech (KRYS) Is Up 7.9% After S&P 400 Move And New KB801 Patent Filing Updatehttps://www.pharmaradar360.com/article/fifarma-se-une-a-alianca-para-a-eliminacao-do-hiv-nas-americas-f454cfc33f89a84bPharma Surgeen2026-07-30T00:03:36.000ZFIFARMA se une à Aliança para a Eliminação do HIV nas Américashttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-5d761ce50a94660dPharma Surgeen2026-07-30T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-e834069d41e93075Pharma Surgeen2026-07-30T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-9c09f11a0c5a5b65Pharma Surgeen2026-07-30T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-ef6875e08aabf779Pharma Surgeen2026-07-30T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-9d1cd0d591ebe880Pharma Surgeen2026-07-30T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-8fda7b74cca97186Pharma Surgeen2026-07-30T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-7595edfcb4bacf41Pharma Surgeen2026-07-30T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-493e85cd0214acffPharma Surgeen2026-07-30T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-291f29425ffdc0a8Pharma Surgeen2026-07-30T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-acf055487841539cPharma Surgeen2026-07-30T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-f1898a816e218040Pharma Surgeen2026-07-30T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-1e5e8b3a112a3cb7Pharma Surgeen2026-07-30T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-9c9b8655c5caaa26Pharma Surgeen2026-07-30T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/home-page-77bbdeb11256516cPharma Surgeen2026-07-30T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/medicare-program-updates-to-the-master-list-of-items-potentially-subject-to-face-fa9cad9b91ad1b04Pharma Surgeen2026-07-30T00:00:00.000ZMedicare Program; Updates to the Master List of Items Potentially Subject to Face-to-Face Encounter and Written Order Prior to Delivery and/or Prior Authorization Requirements; Updates to the Required Face-to-Face Encounter and Written Order Prior to Delivery List; and Updates to the Required Priorhttps://www.pharmaradar360.com/article/butylated-hydroxytoluene-bht-request-for-information-reopening-of-comment-period-252ead25512fc469Pharma Surgeen2026-07-30T00:00:00.000ZButylated Hydroxytoluene (BHT); Request for Information; Reopening of Comment Periodhttps://www.pharmaradar360.com/article/office-of-the-director-national-institutes-of-health-notice-of-meeting-dfa90160a9ccc0aaPharma Surgeen2026-07-30T00:00:00.000ZOffice of the Director, National Institutes of Health; Notice of Meetinghttps://www.pharmaradar360.com/article/office-of-the-secretary-amended-notice-of-meeting-b09adaf1582e0e15Pharma Surgeen2026-07-30T00:00:00.000ZOffice of the Secretary; Amended Notice of Meetinghttps://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-public-comment-requ-6c749fa6d7f34eb8Pharma Surgeen2026-07-30T00:00:00.000ZAgency Information Collection Activities: Proposed Collection: Public Comment Request; Information Collection Request Title: Health Center Program Forms-OMB No. 0915-0285-Revisionhttps://www.pharmaradar360.com/article/announcement-of-the-intent-to-award-single-source-grants-multiple-recipients-for-7b36125533c55e88Pharma Surgeen2026-07-30T00:00:00.000ZAnnouncement of the Intent To Award Single-Source Grants (Multiple Recipients) for Necessary Expenses Directly Related to the Consequences of Hurricanes Fiona and Ianhttps://www.pharmaradar360.com/article/administrative-costs-for-children-in-title-iv-e-foster-care-151a2ee941d51272Pharma Surgeen2026-07-30T00:00:00.000ZAdministrative Costs for Children in Title IV-E Foster Carehttps://www.pharmaradar360.com/article/biosimilar-user-fee-rates-for-fiscal-year-2027-d8c1235e33c86495Pharma Surgeen2026-07-30T00:00:00.000ZBiosimilar User Fee Rates for Fiscal Year 2027https://www.pharmaradar360.com/article/food-safety-modernization-act-voluntary-qualified-importer-program-user-fee-rate-8ff28f383bbbdec4Pharma Surgeen2026-07-30T00:00:00.000ZFood Safety Modernization Act Voluntary Qualified Importer Program User Fee Rate for Fiscal Year 2027https://www.pharmaradar360.com/article/over-the-counter-monograph-drug-user-fee-rates-for-fiscal-year-2027-7661e36b3b13b2e9Pharma Surgeen2026-07-30T00:00:00.000ZOver-the-Counter Monograph Drug User Fee Rates for Fiscal Year 2027https://www.pharmaradar360.com/article/generic-drug-user-fee-rates-for-fiscal-year-2027-c7e23551b9f647b2Pharma Surgeen2026-07-30T00:00:00.000ZGeneric Drug User Fee Rates for Fiscal Year 2027https://www.pharmaradar360.com/article/outsourcing-facility-fee-rates-for-fiscal-year-2027-593ae882eb5aeff2Pharma Surgeen2026-07-30T00:00:00.000ZOutsourcing Facility Fee Rates for Fiscal Year 2027https://www.pharmaradar360.com/article/animal-generic-drug-user-fee-program-rates-and-payment-procedures-for-fiscal-yea-a84d8bd7895c195fPharma Surgeen2026-07-30T00:00:00.000ZAnimal Generic Drug User Fee Program Rates and Payment Procedures for Fiscal Year 2027https://www.pharmaradar360.com/article/animal-drug-user-fee-rates-and-payment-procedures-for-fiscal-year-2027-be13b839dffa2784Pharma Surgeen2026-07-30T00:00:00.000ZAnimal Drug User Fee Rates and Payment Procedures for Fiscal Year 2027https://www.pharmaradar360.com/article/food-safety-modernization-act-third-party-certification-program-user-fee-rate-fo-1ecca3a8b6afb940Pharma Surgeen2026-07-30T00:00:00.000ZFood Safety Modernization Act Third-Party Certification Program User Fee Rate for Fiscal Year 2027https://www.pharmaradar360.com/article/food-safety-modernization-act-domestic-and-foreign-facility-reinspection-recall-a8c8ae52a78a26e1Pharma Surgeen2026-07-30T00:00:00.000ZFood Safety Modernization Act Domestic and Foreign Facility Reinspection, Recall, and Importer Reinspection Fee Rates for Fiscal Year 2027https://www.pharmaradar360.com/article/medical-device-user-fee-rates-for-fiscal-year-2027-6e2aa92b0b39d0b0Pharma Surgeen2026-07-30T00:00:00.000ZMedical Device User Fee Rates for Fiscal Year 2027https://www.pharmaradar360.com/article/prescription-drug-user-fee-rates-for-fiscal-year-2027-7b8444f17d25a519Pharma Surgeen2026-07-30T00:00:00.000ZPrescription Drug User Fee Rates for Fiscal Year 2027https://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meetings-93425e484c351057Pharma Surgeen2026-07-30T00:00:00.000ZCenter for Scientific Review; Notice of Closed Meetingshttps://www.pharmaradar360.com/article/office-of-the-director-national-institutes-of-health-amended-notice-of-meeting-8a7f1e0f87a7d848Pharma Surgeen2026-07-30T00:00:00.000ZOffice of the Director, National Institutes of Health; Amended Notice of Meetinghttps://www.pharmaradar360.com/article/joan-rubinger-n-p-decision-and-order-f33d5dcdbae95a70Pharma Surgeen2026-07-30T00:00:00.000ZJoan Rubinger, N.P.; Decision and Orderhttps://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-96f5b4c5135c534fPharma Surgeen2026-07-30T00:00:00.000ZAgency Information Collection Activities: Proposed Collection; Comment Requesthttps://www.pharmaradar360.com/article/national-center-for-health-statistics-meeting-of-the-icd-10-coordination-and-mai-274c9e55cbd81bdcPharma Surgeen2026-07-30T00:00:00.000ZNational Center for Health Statistics, Meeting of the ICD-10 Coordination and Maintenance Committeehttps://www.pharmaradar360.com/article/drug-label-update-cefpodoxime-proxetil-8858f869e5ff7349Pharma Surgeen2026-07-30T00:00:00.000ZDrug label update: Cefpodoxime Proxetilhttps://www.pharmaradar360.com/article/ember-lifesciences-and-alfresa-corporation-enter-into-capital-and-business-allia-da7c1bb39c6830fePharma Surgeen2026-07-30T00:00:00.000ZEmber LifeSciences and Alfresa Corporation Enter into Capital and Business Alliance to Improve the Quality of the Pharmaceutical Cold Chain in Japanhttps://www.pharmaradar360.com/article/review-of-computer-aided-detection-cad-software-for-tuberculosis-on-chest-x-rays-147c3abbbf57e00aPharma Surgeen2026-07-30T00:00:00.000ZReview of Computer-Aided Detection (CAD) Software for Tuberculosis on Chest X-Rays : A Systematic Review of Randomized Controlled Trial and Primary Studieshttps://www.pharmaradar360.com/article/impacto-de-la-formacion-practica-en-pediatria-en-la-aplicacion-del-proceso-de-at-9076d2cdf64db7b1Pharma Surgeen2026-07-30T00:00:00.000ZImpacto de la formación práctica en pediatría en la aplicación del Proceso de Atención de Enfermería por estudiantes de enfermeríahttps://www.pharmaradar360.com/article/3-clinical-grade-skincare-creams-you-really-shouldn-t-buy-online-d34a5f1696979893Pharma Surgeen2026-07-30T00:00:00.000Z3 clinical-grade skincare creams you really shouldn’t buy onlinehttps://www.pharmaradar360.com/article/intravenous-insulin-protocol-reduces-time-to-target-glucose-in-critically-ill-tr-36fb4870b8cef011Pharma Surgeen2026-07-30T00:00:00.000ZIntravenous insulin protocol reduces time to? target glucose in critically ill trauma and burn? patientshttps://www.pharmaradar360.com/article/case-report-necrotizing-enterocolitis-with-gastric-perforation-in-a-24-day-old-p-094bec4bb63b083aPharma Surgeen2026-07-30T00:00:00.000ZCase Report: Necrotizing Enterocolitis with Gastric Perforation in a 24-day old preterm neonatehttps://www.pharmaradar360.com/article/efficacy-of-gabapentin-versus-trospium-chloride-for-prevention-of-catheter-relat-a5f07981fefd74ddPharma Surgeen2026-07-30T00:00:00.000ZEfficacy of gabapentin versus trospium chloride for prevention of catheter-related bladder discomfort inside the surgical intensive care unit: A prospective, randomised, controlled clinical studyhttps://www.pharmaradar360.com/article/chalcones-as-versatile-scaffolds-in-drug-design-synthesis-structure-activity-rel-85688b23142524ccPharma Surgeen2026-07-30T00:00:00.000ZChalcones as versatile scaffolds in drug design: synthesis, structure–activity relationship (sar), and anticancer potentialhttps://www.pharmaradar360.com/article/beyond-clinical-care-the-influence-of-psychosocial-support-trust-and-service-qua-7f131739f3dbc758Pharma Surgeen2026-07-30T00:00:00.000ZBeyond Clinical Care: The Influence of Psychosocial Support, Trust, and Service Quality on Patient Satisfactionhttps://www.pharmaradar360.com/article/anatomy-driven-dysphagia-after-technically-successful-peroral-endoscopic-myotomy-14e82054035cde4dPharma Surgeen2026-07-30T00:00:00.000ZAnatomy-driven dysphagia after technically successful peroral endoscopic myotomy in sigmoid-shape achalasia: short-term palliation with temporary fully covered self-expanding metal stentshttps://www.pharmaradar360.com/article/percutaneous-endoscopic-gastrostomy-with-jejunal-extension-versus-direct-percuta-c17fc4a40d85a3b4Pharma Surgeen2026-07-30T00:00:00.000ZPercutaneous endoscopic gastrostomy with jejunal extension versus direct percutaneous endoscopic jejunostomy: patient-related outcomes and complicationshttps://www.pharmaradar360.com/article/treatment-procedures-for-intractable-gastroesophageal-reflux-disease-after-peror-f84649beef53cf84Pharma Surgeen2026-07-30T00:00:00.000ZTreatment procedures for intractable gastroesophageal reflux disease after peroral endoscopic myotomy for achalasia: a retrospective study in South Koreahttps://www.pharmaradar360.com/article/digital-leadership-and-individual-employee-performance-in-a-quality-oriented-org-6685b0b11a373b5ePharma Surgeen2026-07-30T00:00:00.000ZDIGITAL LEADERSHIP AND INDIVIDUAL EMPLOYEE PERFORMANCE IN A QUALITY-ORIENTED ORGANIZATIONAL CLIMATE: EVIDENCE FROM THE TURKISH PHARMACEUTICAL INDUSTRYhttps://www.pharmaradar360.com/article/clinical-and-diagnostic-features-of-pediatric-multiple-sclerosis-325a926f3cf9b3c1Pharma Surgeen2026-07-30T00:00:00.000ZCLINICAL AND DIAGNOSTIC FEATURES OF PEDIATRIC MULTIPLE SCLEROSIShttps://www.pharmaradar360.com/article/osint-d416afec4f53cf3cPharma Surgeen2026-07-30T00:00:00.000ZМЕТОДИКА ІНТЕГРАЦІЇ ДАНИХ OSINT У СИСТЕМУ КРИМІНАЛЬНОГО ДОКАЗУВАННЯ НА СТАДІЇ ДОСУДОВОГО РОЗСЛІДУВАННЯhttps://www.pharmaradar360.com/article/confocal-laser-endomicroscopy-with-duodenal-food-challenge-does-not-predict-trig-556e6c78a5935758Pharma Surgeen2026-07-30T00:00:00.000ZConfocal Laser Endomicroscopy With Duodenal Food Challenge Does Not Predict Triggering Food Items in Eosinophilic Esophagitis: Results From a Pilot Trialhttps://www.pharmaradar360.com/article/impact-of-synthesis-temperature-on-the-drug-loading-capacity-of-linde-type-a-zeo-9569f322e8f3c525Pharma Surgeen2026-07-30T00:00:00.000ZImpact of Synthesis Temperature on the Drug Loading Capacity of Linde Type A Zeolitehttps://www.pharmaradar360.com/article/comparative-analysis-of-performance-evaluation-for-stroke-risk-prediction-based-117981bedf30cf25Pharma Surgeen2026-07-30T00:00:00.000ZCOMPARATIVE ANALYSIS OF PERFORMANCE EVALUATION FOR STROKE RISK PREDICTION BASED ON CLINICAL DATAhttps://www.pharmaradar360.com/article/severe-hbv-associated-hepatitis-in-infants-from-the-same-family-two-clinical-cas-44c1a35479b8491aPharma Surgeen2026-07-30T00:00:00.000ZSevere HBV-Associated Hepatitis in Infants from the Same Family: Two Clinical Cases with Different Outcomeshttps://www.pharmaradar360.com/article/nutrition-behaviour-during-pregnancy-eating-twice-as-healthy-a-secondary-analysi-6438d6981ace7338Pharma Surgeen2026-07-30T00:00:00.000ZNutrition Behaviour During Pregnancy: Eating Twice as Healthy? A Secondary Analysis of the Nutrition Component of the NELIP Randomized Controlled Trialhttps://www.pharmaradar360.com/article/the-effects-of-breast-cancer-surgery-on-thoracic-kyphosis-and-the-correlation-be-f874dfed90884965Pharma Surgeen2026-07-30T00:00:00.000ZThe Effects of Breast Cancer Surgery on Thoracic Kyphosis and the Correlation Between Supine CT and Standing X-Rays: A Single-Center Retrospective Studyhttps://www.pharmaradar360.com/article/actual-hydrated-volume-of-acellular-dermal-matrix-in-prepectoral-breast-reconstr-f8f10544d5eb7f0cPharma Surgeen2026-07-30T00:00:00.000ZActual Hydrated Volume of Acellular Dermal Matrix in Prepectoral Breast Reconstructionhttps://www.pharmaradar360.com/article/restoring-ventricular-geometry-left-ventricular-reconstruction-in-a-patient-with-6ce210d563292592Pharma Surgeen2026-07-30T00:00:00.000ZRestoring Ventricular Geometry: Left Ventricular Reconstruction in a Patient with a Giant Left Ventricular Aneurysm and End-Stage Heart Failurehttps://www.pharmaradar360.com/article/assessment-of-care-transition-of-post-covid-19-patients-in-brazil-association-wi-d39044eb90390bf9Pharma Surgeen2026-07-30T00:00:00.000ZAssessment of Care Transition of Post-COVID-19 Patients in Brazil: Association with Sociodemographic and Clinical Characteristicshttps://www.pharmaradar360.com/article/pathogen-characteristics-and-pre-index-clinical-factors-associated-with-multidru-2c034bddb3803ef8Pharma Surgeen2026-07-30T00:00:00.000ZPathogen characteristics and pre-index clinical factors associated with multidrug-resistant organism infections in intensive care unit patientshttps://www.pharmaradar360.com/article/from-benchmark-accuracy-to-pharmacological-credibility-why-mechanistic-explainab-c980b8abe0644634Pharma Surgeen2026-07-30T00:00:00.000ZFrom benchmark accuracy to pharmacological credibility: why mechanistic explainability must define the next generation of AI for drug repurposinghttps://www.pharmaradar360.com/article/integrative-conservative-rehabilitation-for-adolescent-idiopathic-scoliosis-a-ra-dd53d70d3c01b57bPharma Surgeen2026-07-30T00:00:00.000ZIntegrative conservative rehabilitation for adolescent idiopathic scoliosis: a randomized controlled trial of traditional Chinese manual therapy combined with Schroth traininghttps://www.pharmaradar360.com/article/retrospective-analysis-of-the-clinical-value-of-targeted-nursing-using-a-game-ba-9e26695ea4471807Pharma Surgeen2026-07-30T00:00:00.000ZRetrospective analysis of the clinical value of targeted nursing using a game-based model in children undergoing auricular reconstruction for congenital microtiahttps://www.pharmaradar360.com/article/effects-of-curcuma-longa-extract-on-cognitive-function-in-healthy-participants-w-8df4307597a96aeaPharma Surgeen2026-07-30T00:00:00.000ZEffects of Curcuma longa extract on cognitive function in healthy participants with subtle cognitive weaknesses within the normal range: a randomized, double-blind, placebo-controlled trialhttps://www.pharmaradar360.com/article/a-digital-platform-based-stratified-intervention-for-preventing-disability-risk-ab64c10665e10b12Pharma Surgeen2026-07-30T00:00:00.000ZA digital platform-based stratified intervention for preventing disability risk in community-dwelling older adults: study protocol for a randomized multicenter trialhttps://www.pharmaradar360.com/article/development-and-internal-validation-of-machine-learning-models-for-gouty-arthrit-ad6dbdba1b09aa69Pharma Surgeen2026-07-30T00:00:00.000ZDevelopment and internal validation of machine learning models for gouty arthritis classification using routine clinical variables: a retrospective studyhttps://www.pharmaradar360.com/article/clinical-study-of-remimazolam-combined-with-ultrasound-guided-superior-laryngeal-05d06729d83c8122Pharma Surgeen2026-07-30T00:00:00.000ZClinical study of remimazolam combined with ultrasound-guided superior laryngeal nerve block in elderly patients with coronary heart disease undergoing bronchoscopyhttps://www.pharmaradar360.com/article/efficacy-and-safety-of-the-traditional-chinese-medicine-formulation-bl-1-for-the-0047ca52d4fbc1ccPharma Surgeen2026-07-30T00:00:00.000ZEfficacy and safety of the traditional Chinese medicine formulation BL-1 for the treatment of low anterior resection syndrome: study protocol for a double-blind, randomized, placebo-controlled trialhttps://www.pharmaradar360.com/article/hepatic-tubercular-abscess-due-to-paradoxical-tb-iris-during-anti-tubercular-the-cd2360dda4da89a2Pharma Surgeen2026-07-30T00:00:00.000ZHepatic tubercular abscess due to paradoxical TB-IRIS during anti-tubercular therapy with concurrent drug-induced liver injury: a case reporthttps://www.pharmaradar360.com/article/pediatric-epidermolysis-bullosa-amp-8211-psychosocial-impact-and-the-importance-3c8121521c4dc288Pharma Surgeen2026-07-30T00:00:00.000ZPediatric epidermolysis bullosa – psychosocial impact and the importance of palliative care based on 5 clinical caseshttps://www.pharmaradar360.com/article/primary-erythromelalgia-a-clinical-diagnosis-f45fea7ba3e5c702Pharma Surgeen2026-07-30T00:00:00.000ZPrimary erythromelalgia: a clinical diagnosishttps://www.pharmaradar360.com/article/serial-clinical-observation-in-early-neonatal-sepsis-insights-from-a-national-po-55922526010f7b68Pharma Surgeen2026-07-30T00:00:00.000ZSerial clinical observation in early neonatal sepsis: insights from a national portuguese surveyhttps://www.pharmaradar360.com/article/f144db071f3c5f3dPharma Surgeen2026-07-30T00:00:00.000ZКоличественная оценка результатов иммуногистохимического исследования: современные подходы и ограничения методаhttps://www.pharmaradar360.com/article/12-38be10c07e11f794Pharma Surgeen2026-07-30T00:00:00.000ZСистемный анализ трёхэтапной схемы сегментационного предобучения для выявления признаков инфаркта миокарда по электрокардиограмме в 12 отведенияхhttps://www.pharmaradar360.com/article/lt-i-gt-chondrus-armatus-lt-i-gt-e9638e0dda937c1ePharma Surgeen2026-07-30T00:00:00.000ZАнтиоксидантная и радикал-связывающая активность нативных и деполимеризованных κ- и λ-каррагинанов красной водоросли <i>Chondrus armatus</i>https://www.pharmaradar360.com/article/the-effectiveness-of-acceptance-and-commitment-therapy-on-marital-functioning-em-826b930cb29f7b8dPharma Surgeen2026-07-30T00:00:00.000ZThe Effectiveness of Acceptance and Commitment Therapy on Marital Functioning, Emotion Regulation, and Secondary Traumatic Stress Symptoms in Wives of Soldiers with Post-Traumatic Stress Disorder: A Randomized Controlled Trialhttps://www.pharmaradar360.com/article/long-term-effectiveness-of-combination-antiretroviral-therapy-and-drug-resistanc-c855048c27aa50a3Pharma Surgeen2026-07-30T00:00:00.000ZLong-Term Effectiveness of combination Antiretroviral Therapy and Drug Resistance Patterns Among People living with HIV in Benghazi, Libya: Retrospective cohort Study (2009 – 2014)https://www.pharmaradar360.com/article/clinical-outcomes-following-implementation-of-an-early-enteral-nutrition-initiat-ae017edd08f8f590Pharma Surgeen2026-07-30T00:00:00.000ZClinical outcomes following implementation of an early enteral nutrition initiation and monitoring approach in critically ill ventilated patients: a historical-control observational studyhttps://www.pharmaradar360.com/article/the-effect-of-an-indirect-anchorage-reinforcement-device-on-maxillary-anterior-i-3bb17bacddb8650bPharma Surgeen2026-07-30T00:00:00.000ZThe effect of an indirect anchorage reinforcement device on maxillary anterior intrusion with clear aligners: a three-dimensional finite element analysis and exploratory clinical validationhttps://www.pharmaradar360.com/article/organelle-specific-mechanisms-and-ai-guided-stratification-in-gut-renal-vascular-0ce5ca2d5c618abfPharma Surgeen2026-07-30T00:00:00.000ZOrganelle-specific mechanisms and AI-guided stratification in gut-renal-vascular axis modulationhttps://www.pharmaradar360.com/article/eight-weeks-of-focal-muscle-vibration-shows-improvements-in-muscle-co-ordination-6fdec247a7d14e99Pharma Surgeen2026-07-30T00:00:00.000ZEight weeks of focal muscle vibration shows improvements in muscle co-ordination and co-contraction in cerebral palsy children: a randomized control trialhttps://www.pharmaradar360.com/article/trial-reported-arthralgia-of-androgen-deprivation-therapy-plus-androgen-receptor-990f9173aab8c8e7Pharma Surgeen2026-07-30T00:00:00.000ZTrial-reported arthralgia of androgen deprivation therapy plus androgen receptor signaling inhibitors in prostate cancer: evidence from phase III randomized trialshttps://www.pharmaradar360.com/article/artificially-intelligent-simulated-patients-in-undergraduate-surgical-teaching-a-e09bb84f55731098Pharma Surgeen2026-07-30T00:00:00.000ZArtificially Intelligent Simulated Patients in Undergraduate Surgical Teaching: A Single Blinded Randomized Controlled Studyhttps://www.pharmaradar360.com/article/efficacy-of-targeted-neuromodulation-treatments-a-clinical-report-90f1b12c9a93676fPharma Surgeen2026-07-30T00:00:00.000ZEfficacy of targeted neuromodulation treatments: a clinical reporthttps://www.pharmaradar360.com/article/intraocular-retinoblastoma-features-and-treatment-outcomes-according-to-patient-f415634a52e73d73Pharma Surgeen2026-07-30T00:00:00.000ZIntraocular retinoblastoma features and treatment outcomes according to patient age at initial presentationhttps://www.pharmaradar360.com/article/automated-readings-of-imaging-reports-by-natural-language-processing-nlp-supplem-fbc347139701a483Pharma Surgeen2026-07-30T00:00:00.000ZAutomated readings of imaging reports by natural language processing (NLP) supplemented by clinical data predict disease course in children and adults with Crohn’s disease: report from the epi-IIRNhttps://www.pharmaradar360.com/article/safety-feasibility-and-preliminary-clinical-outcomes-of-psilocybin-assisted-ther-2f46c63a83c2928aPharma Surgeen2026-07-30T00:00:00.000ZSafety, feasibility, and preliminary clinical outcomes of psilocybin-assisted therapy for veterans with severe, treatment-resistant PTSD: an open-label pilot clinical trialhttps://www.pharmaradar360.com/article/clinical-toxicity-of-adcs-and-ici-adc-combinations-mechanisms-patterns-and-manag-20b0c8425a12116fPharma Surgeen2026-07-30T00:00:00.000ZClinical toxicity of ADCs and ICI–ADC combinations: mechanisms, patterns and managementhttps://www.pharmaradar360.com/article/trial-by-fire-uncertainty-and-adaptive-management-in-forest-ecology-c60abc33dfcea279Pharma Surgeen2026-07-30T00:00:00.000ZTrial by Fire: Uncertainty and Adaptive Management in Forest Ecologyhttps://www.pharmaradar360.com/article/comparing-research-priorities-and-approaches-in-appalachia-and-broader-rural-hea-3f536c3a34c76336Pharma Surgeen2026-07-30T00:00:00.000ZComparing research priorities and approaches in Appalachia and Broader Rural Health Contexts: A Scoping reviewhttps://www.pharmaradar360.com/article/recategorizing-sc-ctsi-s-online-educational-library-using-joint-task-force-core-e631bb3e4b1ea7c8Pharma Surgeen2026-07-30T00:00:00.000ZRecategorizing SC CTSI’s Online Educational Library Using Joint Task Force Core Competencies for Research Professionals: Outlining the Process and Lessons Learnedhttps://www.pharmaradar360.com/article/addressing-the-forgotten-dimension-protocol-for-a-convergent-mixed-methods-study-bc8b32e5df34205dPharma Surgeen2026-07-30T00:00:00.000ZAddressing the Forgotten Dimension: Protocol for a Convergent Mixed-methods Study of Sexual Health in Neurological Rehabilitation Patients and Their Care Teamhttps://www.pharmaradar360.com/article/serum-neurofilament-light-protein-as-a-biomarker-across-the-cognitive-decline-co-b37bb8db3f36734cPharma Surgeen2026-07-30T00:00:00.000ZSerum neurofilament light protein as a biomarker across the cognitive decline continuum: a cross-sectional study from an Indian cohorthttps://www.pharmaradar360.com/article/simulation-based-predictions-to-support-the-development-of-a-pediatric-fixed-dos-318dc50acc5a4fbcPharma Surgeen2026-07-30T00:00:00.000ZSimulation-Based Predictions to Support the Development of a Pediatric Fixed-Dose Combination of Dolutegravir/Emtricitabine/Tenofovir Alafenamide Fumaratehttps://www.pharmaradar360.com/article/midodrine-associated-posterior-reversible-encephalopathy-syndrome-following-medu-6b6f745b543ff565Pharma Surgeen2026-07-30T00:00:00.000ZMidodrine‐Associated Posterior Reversible Encephalopathy Syndrome Following Medullary and Cervical Spinal Cord Infarction in a Childhttps://www.pharmaradar360.com/article/comment-on-survival-improvement-with-steroid-use-for-pulmonary-veno-occlusive-di-6c3e69e4692a8e77Pharma Surgeen2026-07-30T00:00:00.000ZComment on “Survival Improvement With Steroid Use for Pulmonary Veno‐Occlusive Disease With the Aid of Pulmonary Vasodilators and Tyrosine‐Kinase Inhibitor, a Retrospective Study”https://www.pharmaradar360.com/article/fifarma-joins-the-alliance-for-the-elimination-of-hiv-in-the-americas-92e7b95ac15f4357Pharma Surgeen2026-07-29T23:06:27.000ZFIFARMA Joins the Alliance for the Elimination of HIV in the Americashttps://www.pharmaradar360.com/article/early-surgery-for-acute-eye-infection-offers-hope-to-patients-b80f45b163106c2fPharma Surgeen2026-07-29T23:04:04.000ZEarly surgery for acute eye infection offers hope to patientshttps://www.pharmaradar360.com/article/fda-finalizes-three-guidances-to-broaden-cancer-clinical-trial-eligibility-d512107e3848d16dPharma Surgeen2026-07-29T22:30:00.000ZFDA Finalizes Three Guidances to Broaden Cancer Clinical Trial Eligibilityhttps://www.pharmaradar360.com/article/elix-and-university-of-vienna-aim-to-advance-drug-discovery-using-ai-1483519727381b92Pharma Surgeen2026-07-29T22:29:00.000ZElix and University of Vienna Aim to Advance Drug Discovery Using AIhttps://www.pharmaradar360.com/article/psm-joins-psi-rx360-and-pdsa-in-letter-urging-fda-to-protect-the-traceable-drug-0e14ebe773daef1bPharma Surgeen2026-07-29T22:23:22.000ZPSM joins PSI, Rx360 and PDSA in letter urging FDA to protect the traceable drug supplyhttps://www.pharmaradar360.com/article/fda-expert-panel-recommends-against-approval-of-capricor-s-duchenne-drug-108439ff7bea2cc8Pharma Surgeen2026-07-29T22:21:58.000ZFDA expert panel recommends against approval of Capricor’s Duchenne drughttps://www.pharmaradar360.com/article/dod-biotech-public-co-ltd-revenue-breakdown-set-dod-2c9dccc2132ac3c1Pharma Surgeen2026-07-29T22:18:54.000ZDOD Biotech Public Co., Ltd. Revenue Breakdown – SET:DODhttps://www.pharmaradar360.com/article/fifarma-se-suma-a-la-alianza-para-la-eliminacion-del-vih-en-las-americas-90af3291abe7ffeaPharma Surgeen2026-07-29T22:11:18.000ZFIFARMA se suma a la Alianza para la Eliminación del VIH en las Américashttps://www.pharmaradar360.com/article/9th-circ-revives-biotech-worker-s-pension-plan-suit-31ca102a4a1de522Pharma Surgeen2026-07-29T22:08:00.000Z9th Circ. Revives Biotech Worker's Pension Plan Suithttps://www.pharmaradar360.com/article/trip-advisor-fda-publishes-guidance-on-psychedelic-drug-trials-cf9d22c4b79a95baPharma Surgeen2026-07-29T22:01:35.000ZTrip Advisor: FDA Publishes Guidance on Psychedelic Drug Trialshttps://www.pharmaradar360.com/article/roche-unveils-preventron-a-phase-3-prevention-trial-of-trontinemab-in-cognitivel-d019deefca17f021Pharma Surgeen2026-07-29T22:00:00.000ZRoche Unveils PrevenTRON, a Phase 3 Prevention Trial of Trontinemab in Cognitively Unimpaired Individuals at High Risk of Alzheimer Declinehttps://www.pharmaradar360.com/article/dr-sven-k-weber-succeeds-adriaan-moelker-as-ceo-of-brain-biotech-ag-b96022ab0d559643Pharma Surgeen2026-07-29T21:55:12.000ZDr. Sven K. Weber Succeeds Adriaan Moelker as CEO of BRAIN Biotech AGhttps://www.pharmaradar360.com/article/what-the-fda-s-peptide-vote-actually-means-da657b5b70715f3fPharma Surgeen2026-07-29T21:55:00.000ZWhat the FDA’s Peptide Vote Actually Meanshttps://www.pharmaradar360.com/article/goldman-backed-biotech-attovia-seeks-212-5-million-in-us-ipo-258903e3b3672baePharma Surgeen2026-07-29T21:53:01.000ZGoldman-Backed Biotech Attovia Seeks $212.5 Million in US IPOhttps://www.pharmaradar360.com/article/maplight-ceo-on-what-investors-missed-in-the-biotech-s-schizophrenia-data-cd12f53247089b3aPharma Surgeen2026-07-29T21:50:10.000ZMapLight CEO on what investors missed in the biotech’s schizophrenia datahttps://www.pharmaradar360.com/article/259-pro-abortion-lawmakers-urge-court-to-keep-abortion-pill-access-easy-2e2a174ad6ca739cPharma Surgeen2026-07-29T21:50:02.000Z259 pro-abortion lawmakers urge court to keep abortion pill access easyhttps://www.pharmaradar360.com/article/melanoma-biotech-secures-nasdaq-listing-via-all-share-merger-a8ce76a8c00d2c3fPharma Surgeen2026-07-29T21:17:38.000ZMelanoma Biotech Secures Nasdaq Listing via All-Share Mergerhttps://www.pharmaradar360.com/article/pharmacyte-biotech-inc-fy-2026-revenue-0-net-income-23-21m-eps-2-77-10-k-summary-849309b8da368227Pharma Surgeen2026-07-29T21:05:01.000ZPharmaCyte Biotech, Inc. FY 2026: Revenue $0 Net income ($23.21M), EPS ($2.77) — 10-K Summaryhttps://www.pharmaradar360.com/article/vivozon-expands-onapra-into-chronic-pain-targets-us-phase-3-and-tech-transfer-ch-2259e02c5c0e7243Pharma Surgeen2026-07-29T21:01:00.000ZVivozon expands Onapra into chronic pain, targets US phase 3 and tech transfer - CHOSUNBIZhttps://www.pharmaradar360.com/article/what-to-know-about-pharmaceutical-tariffs-b7c0ee9e6f3e6dabPharma Surgeen2026-07-29T20:32:08.000ZWhat to know about pharmaceutical tariffshttps://www.pharmaradar360.com/article/viking-therapeutics-reports-second-quarter-2026-financial-results-and-provides-c-0be95e88105172d5Pharma Surgeen2026-07-29T20:05:00.000ZViking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updatehttps://www.pharmaradar360.com/article/fda-approves-first-ever-freeze-dried-plasma-product-17617af839bb4b04Pharma Surgeen2026-07-29T20:01:09.000ZFDA Approves First-Ever Freeze-Dried Plasma Producthttps://www.pharmaradar360.com/article/arkansas-suspends-enforcement-of-law-limiting-pharmaceutical-distribution-525eaa74400f0b04Pharma Surgeen2026-07-29T20:00:00.000ZArkansas suspends enforcement of law limiting pharmaceutical distributionhttps://www.pharmaradar360.com/article/a-new-adhd-drug-just-got-fda-approval-here-s-what-makes-it-different-9564906794f54dfbPharma Surgeen2026-07-29T19:44:56.000ZA new ADHD drug just got FDA approval. Here's what makes it different.https://www.pharmaradar360.com/article/landmark-phase-iii-trial-finds-cell-therapy-slows-muscle-decline-in-advanced-dmd-8b500804c6789fdePharma Surgeen2026-07-29T19:26:16.000ZLandmark Phase III Trial Finds Cell Therapy Slows Muscle Decline in Advanced DMDhttps://www.pharmaradar360.com/article/teva-pharmaceutical-industries-ltd-teva-q2-2026-earnings-call-highlights-strong-a5c26498f116a333Pharma Surgeen2026-07-29T19:03:04.000ZTeva Pharmaceutical Industries Ltd (TEVA) Q2 2026 Earnings Call Highlights: Strong Innovative ...https://www.pharmaradar360.com/article/greenberg-traurig-advises-entera-bio-in-record-275m-israeli-biotech-pipe-6bbc7450f87bc833Pharma Surgeen2026-07-29T19:00:00.000ZGreenberg Traurig Advises Entera Bio in Record $275M Israeli Biotech PIPEhttps://www.pharmaradar360.com/article/fda-approves-viatris-s-gwyn-lo-pharmexec-1d0c061316452c89Pharma Surgeen2026-07-29T18:47:05.000ZFDA Approves Viatris's Gwyn Lo | PharmExechttps://www.pharmaradar360.com/article/new-singham-in-town-maharashtra-fda-chief-defends-crackdown-on-mumbai-eateries-c262ef5674321f6aPharma Surgeen2026-07-29T18:26:01.000ZNew Singham in town? Maharashtra FDA chief defends crackdown on Mumbai eaterieshttps://www.pharmaradar360.com/article/opinion-the-u-s-could-become-dependent-on-china-for-life-saving-drugs-b0c2402ef42da1bcPharma Surgeen2026-07-29T18:15:00.000ZOpinion | The U.S. could become dependent on China for life-saving drugshttps://www.pharmaradar360.com/article/interfarma-integra-o-cncp-e-amplia-contribuicao-ao-combate-a-pirataria-e-defesa-d48fd9199cd0c8f4Pharma Surgeen2026-07-29T18:08:32.000ZInterfarma integra o CNCP e amplia contribuição ao combate à pirataria e defesa da inovaçãohttps://www.pharmaradar360.com/article/pancreatic-cancer-drug-doubled-survival-in-phase-3-trial-who-qualifies-for-expan-fa1dadd7cfb81dbfPharma Surgeen2026-07-29T18:00:17.000ZPancreatic Cancer Drug Doubled Survival in Phase 3 Trial. Who Qualifies for Expanded Access?https://www.pharmaradar360.com/article/uconn-school-of-pharmacy-and-pharmaceutical-sciences-professor-xiuling-lu-receiv-3ab3719996294f57Pharma Surgeen2026-07-29T17:52:01.000ZUConn School of Pharmacy and Pharmaceutical Sciences Professor Xiuling Lu Receives Director Promotionhttps://www.pharmaradar360.com/article/six-months-in-a-2026-progress-check-on-pharma-dealmaking-access-and-commercializ-3dafa39b5458687aPharma Surgeen2026-07-29T17:41:07.000ZSix Months In: A 2026 Progress Check on Pharma Dealmaking, Access and Commercializationhttps://www.pharmaradar360.com/article/fly-here-too-what-can-we-do-bombay-hc-s-wry-remark-during-hotel-cockroach-row-e4f8aa0ee0c6017ePharma Surgeen2026-07-29T17:23:08.000Z'Fly Here Too, What Can We Do?' Bombay HC's Wry Remark During Hotel Cockroach Rowhttps://www.pharmaradar360.com/article/fda-suspends-licences-of-21-food-establishments-in-pune-ee292c813898eb79Pharma Surgeen2026-07-29T16:50:39.000ZFDA suspends licences of 21 food establishments in Punehttps://www.pharmaradar360.com/article/mumbai-news-live-updates-parsi-dairy-farm-reopens-in-mumbai-after-fda-lifts-lice-a86669406ee38869Pharma Surgeen2026-07-29T16:40:00.000ZMumbai News LIVE Updates: Parsi Dairy Farm reopens in Mumbai after FDA lifts licence suspensionhttps://www.pharmaradar360.com/article/food-and-drug-administration-commissioner-tukaram-munde-says-goal-is-safe-food-s-d531599d7ea00b23Pharma Surgeen2026-07-29T16:36:47.000ZFood and Drug Administration Commissioner Tukaram Munde says goal is safe food, safe drugs, safe Maharashtra - India Todayhttps://www.pharmaradar360.com/article/industry-report-a-progress-check-on-dealmaking-access-and-commercialization-534691d404b17e49Pharma Surgeen2026-07-29T16:36:07.000ZIndustry Report: A Progress Check on Dealmaking, Access and Commercializationhttps://www.pharmaradar360.com/article/caldera-vidya-add-to-recent-flurry-of-biotech-mergers-07404531de03f29ePharma Surgeen2026-07-29T16:32:30.000ZCaldera, Vidya add to recent flurry of biotech mergershttps://www.pharmaradar360.com/article/krystal-biotech-krys-after-the-kb801-update-and-why-valuation-still-splits-opini-977cd7e9ea9f0cc5Pharma Surgeen2026-07-29T16:32:01.000ZKrystal Biotech (KRYS) After The KB801 Update And Why Valuation Still Splits Opinionhttps://www.pharmaradar360.com/article/us-biotech-hits-back-at-merck-over-tissue-regrowth-patent-fb3e92039d4f4186Pharma Surgeen2026-07-29T16:32:00.000ZUS Biotech Hits Back At Merck Over Tissue Regrowth Patenthttps://www.pharmaradar360.com/article/adcom-expected-for-uniqure-s-huntington-s-gene-therapy-chief-medical-officer-say-d69190bfbe03c1d8Pharma Surgeen2026-07-29T15:52:55.000ZAdCom expected for uniQure’s Huntington’s gene therapy, chief medical officer sayshttps://www.pharmaradar360.com/article/cormedix-therapeutics-to-report-second-quarter-2026-financial-results-and-provid-0fc5410b3d92559fPharma Surgeen2026-07-29T15:48:30.000ZCORMEDIX THERAPEUTICS TO REPORT SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON AUGUST 13, 2026https://www.pharmaradar360.com/article/news-montreal-s-biotech-property-market-loses-momentum-after-years-of-growth-5fffcf98c91c5973Pharma Surgeen2026-07-29T15:47:51.000ZNews | Montreal's biotech property market loses momentum after years of growthhttps://www.pharmaradar360.com/article/notifiable-diseases-causative-agents-reports-for-2026-32900b46450305d4Pharma Surgeen2026-07-29T15:17:14.000ZNotifiable diseases: causative agents reports for 2026https://www.pharmaradar360.com/article/merck-announces-fourth-quarter-2026-dividend-50947ea895407a1ePharma Surgeen2026-07-29T15:04:00.000ZMerck Announces Fourth-Quarter 2026 Dividendhttps://www.pharmaradar360.com/article/etf-talk-engineer-gains-through-this-biotech-etf-3d2a12a06e1af8bdPharma Surgeen2026-07-29T15:00:19.000ZETF Talk: Engineer Gains Through This Biotech ETFhttps://www.pharmaradar360.com/article/pharma-packaging-jobs-to-grow-5-4-through-2034-b9bbff2bf53b410ePharma Surgeen2026-07-29T15:00:00.000ZPharma Packaging Jobs to Grow 5.4% Through 2034https://www.pharmaradar360.com/article/seventeen-peptide-guidance-revised-what-developers-need-to-know-b00e81c2c02dd747Pharma Surgeen2026-07-29T14:58:39.000ZSeventeen Peptide Guidance Revised: What Developers Need to Knowhttps://www.pharmaradar360.com/article/fda-regenerative-medicine-approvals-show-growing-momentum-2637f03545716749Pharma Surgeen2026-07-29T14:55:43.000ZFDA regenerative medicine approvals show growing momentumhttps://www.pharmaradar360.com/article/moleculin-biotech-files-registration-statement-for-public-offering-shares-fall-acb745e917175c5aPharma Surgeen2026-07-29T14:45:49.000ZMoleculin Biotech Files Registration Statement for Public Offering; Shares Fallhttps://www.pharmaradar360.com/article/why-biotech-is-outpacing-the-ai-slump-3-stocks-to-watch-2026-07-29-investing-new-ef798d58fdd398a3Pharma Surgeen2026-07-29T14:45:00.000ZWhy biotech is outpacing the AI slump: 3 stocks to watch | 2026-07-29 | Investing Newshttps://www.pharmaradar360.com/article/gsk-eyes-future-growth-with-cost-cutting-plan-amid-promising-q2-b076e1774dd228e4Pharma Surgeen2026-07-29T14:40:43.000ZGSK eyes future growth with cost-cutting plan amid promising Q2https://www.pharmaradar360.com/article/where-do-we-stand-on-pharmaceutical-tariffs-431df8cda15fc67dPharma Surgeen2026-07-29T14:38:37.000ZWhere do we stand on pharmaceutical tariffs?https://www.pharmaradar360.com/article/teva-pharmaceutical-industries-nyse-teva-trading-8-2-higher-after-analyst-upgrad-59d570920d199dfePharma Surgeen2026-07-29T14:31:50.000ZTeva Pharmaceutical Industries (NYSE:TEVA) Trading 8.2% Higher After Analyst Upgradehttps://www.pharmaradar360.com/article/novo-nordisk-fails-to-dismiss-lawsuit-over-cagrisema-readout-a5796bc22082c43ePharma Surgeen2026-07-29T14:30:05.000ZNovo Nordisk fails to dismiss lawsuit over CagriSema readouthttps://www.pharmaradar360.com/article/ftre-raised-full-year-guidance-after-strong-biotech-driven-bookings-and-improved-a833c101c7dce7bcPharma Surgeen2026-07-29T14:24:52.000ZFTRE: Raised full-year guidance after strong biotech-driven bookings and improved operational efficiencyhttps://www.pharmaradar360.com/article/a-recipe-for-danger-social-media-challenges-involving-medicines-1377843511cd2e61Pharma Surgeen2026-07-29T14:21:38.000ZA Recipe for Danger: Social media challenges involving medicineshttps://www.pharmaradar360.com/article/the-biotech-growth-trust-plc-net-asset-value-s-b87159afbab2a964Pharma Surgeen2026-07-29T14:11:00.000ZThe Biotech Growth Trust PLC - Net Asset Value(s)https://www.pharmaradar360.com/article/capricor-therapeutics-announces-lancet-publication-of-positive-phase-3-hope-3-tr-f13eb2ed748a3c64Pharma Surgeen2026-07-29T14:10:00.000ZCapricor Therapeutics Announces Lancet Publication of Positive Phase 3 HOPE-3 Trial Results for Deramiocel in Duchenne Muscular Dystrophyhttps://www.pharmaradar360.com/article/atea-pharmaceuticals-achieves-phase-3-success-in-hepatitis-c-trial-5426bac590308403Pharma Surgeen2026-07-29T14:06:43.000ZAtea Pharmaceuticals Achieves Phase 3 Success in Hepatitis C Trialhttps://www.pharmaradar360.com/article/fda-grants-fast-track-designation-to-insilico-s-ai-designed-mesothelioma-drug-ca-e406705f4d0a46c0Pharma Surgeen2026-07-29T14:06:00.000ZFDA grants fast track designation to Insilico's AI-designed mesothelioma drug candidatehttps://www.pharmaradar360.com/article/no-chips-no-sugary-drinks-near-schools-maharashtra-fda-imposes-strict-50-metre-b-75fd420812d7c58bPharma Surgeen2026-07-29T14:06:00.000ZNo chips, no sugary drinks near schools: Maharashtra FDA imposes strict 50-metre banhttps://www.pharmaradar360.com/article/phase-3-trial-shows-investigational-cell-therapy-slowed-disease-progression-in-d-aa3bdc720f78d198Pharma Surgeen2026-07-29T14:02:12.000ZPhase 3 trial shows investigational cell therapy slowed disease progression in Duchenne muscular dystrophyhttps://www.pharmaradar360.com/article/china-biotech-sector-fears-policy-backlash-after-girl-dies-in-gene-editing-trial-35690fe3bfa88260Pharma Surgeen2026-07-29T14:00:14.000ZChina biotech sector fears policy backlash after girl dies in gene-editing trialhttps://www.pharmaradar360.com/article/healthy-planet-healthy-people-the-innovative-pharmaceutical-industry-s-contribut-b38b6b4fbd70432fPharma Surgeen2026-07-29T13:54:31.000ZHealthy planet, healthy people: The innovative pharmaceutical industry's contribution to the Kunming-Montreal Global Biodiversity Frameworkhttps://www.pharmaradar360.com/article/transcript-teva-pharmaceutical-industries-limited-q2-2026-earnings-call-jul-29-2-59f3e641d158f596Pharma Surgeen2026-07-29T13:50:20.000ZTranscript : Teva Pharmaceutical Industries Limited, Q2 2026 Earnings Call, Jul 29, 2026https://www.pharmaradar360.com/article/pcsa-stock-for-stock-acquisition-and-200m-pipe-create-a-btk-focused-biotech-with-7a25614b6d4087a0Pharma Surgeen2026-07-29T13:44:55.000ZPCSA: Stock-for-stock acquisition and $200M PIPE create a BTK-focused biotech with runway into 2029https://www.pharmaradar360.com/article/actualizacion-del-codigo-alimentario-argentino-sobre-disposiciones-para-envases-325559b3c341ae23Pharma Surgeen2026-07-29T13:44:38.000ZActualización del Código Alimentario Argentino sobre disposiciones para envases, revestimientos, utensilios, tapas y equipamientos metálicos en contacto con alimentoshttps://www.pharmaradar360.com/article/nhs-england-seeking-provider-for-pharmacy-technician-clinical-training-0577b1db8f6396f3Pharma Surgeen2026-07-29T13:39:09.000ZNHS England seeking provider for pharmacy technician clinical traininghttps://www.pharmaradar360.com/article/pharmalittle-we-re-reading-about-a-fugitive-who-became-a-biotech-exec-a-hospital-c2f070227193af12Pharma Surgeen2026-07-29T13:38:25.000ZPharmalittle: We're reading about a fugitive who became a biotech exec, a hospital suing Lilly, and morehttps://www.pharmaradar360.com/article/state-street-vs-first-trust-is-a-broad-healthcare-or-biotech-focus-better-for-yo-36319f4b3a232225Pharma Surgeen2026-07-29T13:32:55.000ZState Street vs. First Trust: Is a Broad Healthcare or Biotech Focus Better for Your Portfolio?https://www.pharmaradar360.com/article/killing-slime-an-ai-first-biotech-solution-419199dc38c4c60bPharma Surgeen2026-07-29T13:30:38.000ZKilling slime: an AI-first biotech solutionhttps://www.pharmaradar360.com/article/callan-jmb-and-alabama-state-university-break-ground-on-atlas-complex-launching-2f71ebfc71305898Pharma Surgeen2026-07-29T13:26:06.000ZCallan JMB and Alabama State University Break Ground on Atlas Complex, Launching an Unprecedented Strategic Partnership to Advance U.S. Pharmaceutical Manufacturing and Supply Chain Resiliencehttps://www.pharmaradar360.com/article/mid-year-check-in-how-direct-to-patient-momentum-is-accelerating-113d44a55a383f26Pharma Surgeen2026-07-29T13:01:18.000ZMid-Year Check-In: How Direct-to-Patient Momentum Is Acceleratinghttps://www.pharmaradar360.com/article/respiratory-syncytial-virus-rsv-vaccine-pgd-template-eb0199df34763a87Pharma Surgeen2026-07-29T13:00:04.000ZRespiratory syncytial virus (RSV) vaccine: PGD templatehttps://www.pharmaradar360.com/article/immunisation-patient-group-direction-pgd-templates-1af7ede7c1c283c6Pharma Surgeen2026-07-29T13:00:04.000ZImmunisation patient group direction (PGD) templateshttps://www.pharmaradar360.com/article/respiratory-syncytial-virus-rsv-vaccine-vgd-template-16eda7af24013a7ePharma Surgeen2026-07-29T13:00:00.000ZRespiratory syncytial virus (RSV) vaccine: VGD templatehttps://www.pharmaradar360.com/article/fda-clears-medicus-to-start-gorlin-syndrome-drug-study-04b6f1bfa2357f4fPharma Surgeen2026-07-29T13:00:00.000ZFDA Clears Medicus to Start Gorlin Syndrome Drug Studyhttps://www.pharmaradar360.com/article/reverse-mergers-are-increasingly-popular-caldera-hops-on-synlogic-s-nasdaq-listi-09e14fd75e899e08Pharma Surgeen2026-07-29T12:56:37.000Z‘Reverse mergers are increasingly popular’: Caldera hops on Synlogic’s Nasdaq listinghttps://www.pharmaradar360.com/article/vaccine-update-30d4e36f5ec7eb5aPharma Surgeen2026-07-29T12:37:11.000ZVaccine updatehttps://www.pharmaradar360.com/article/this-is-india-take-a-realistic-view-high-court-to-fda-over-food-safety-crackdown-5f72d5a4f250c666Pharma Surgeen2026-07-29T12:34:53.000ZThis is India, take a realistic view: High Court to FDA over food safety crackdownhttps://www.pharmaradar360.com/article/splash-beverage-group-expands-cannepil-platform-into-6bb8018c32594cc9Pharma Surgeen2026-07-29T12:30:00.000ZSplash Beverage Group Expands CannEpil® Platform intohttps://www.pharmaradar360.com/article/lb-pharmaceuticals-announces-150-million-private-placement-702702c95a43501bPharma Surgeen2026-07-29T12:22:46.000ZLB Pharmaceuticals Announces $150 Million Private Placementhttps://www.pharmaradar360.com/article/gerresheimer-sells-centor-and-primary-packaging-plastics-business-for-around-1-5-830ea0d29841de70Pharma Surgeen2026-07-29T12:19:29.000ZGerresheimer Sells Centor And Primary Packaging Plastics Business For Around €1.5 Billionhttps://www.pharmaradar360.com/article/brain-biotech-ag-appoints-dr-sven-k-weber-as-new-chairman-of-the-executive-board-df84e5f98732b2ccPharma Surgeen2026-07-29T12:19:04.000ZBRAIN Biotech AG Appoints Dr. Sven K. Weber as New Chairman of the Executive Board, Effective October 1, 2026https://www.pharmaradar360.com/article/teva-pharmaceutical-industries-nyse-teva-issues-fy-2026-earnings-guidance-f97b00f77d228828Pharma Surgeen2026-07-29T12:13:55.000ZTeva Pharmaceutical Industries (NYSE:TEVA) Issues FY 2026 Earnings Guidancehttps://www.pharmaradar360.com/article/easy-read-guide-to-the-mmrv-vaccination-02488ed69de507a8Pharma Surgeen2026-07-29T12:09:14.000ZEasy read guide to the MMRV vaccinationhttps://www.pharmaradar360.com/article/menb-vaccination-programme-eligible-residential-further-education-settings-ea1c926b97083608Pharma Surgeen2026-07-29T12:06:19.000ZMenB vaccination programme: eligible residential further education settingshttps://www.pharmaradar360.com/article/watch-out-eli-lilly-and-novo-nordisk-amgen-s-monthly-weight-loss-drug-has-6-phas-bae32f27c17dc785Pharma Surgeen2026-07-29T12:04:39.000ZWatch Out, Eli Lilly and Novo Nordisk: Amgen's Monthly Weight Loss Drug Has 6 Phase 3 Trials Running -- and It's Coming for Your Patientshttps://www.pharmaradar360.com/article/teva-pharmaceutical-industries-releases-q2-2026-financial-results-38e74857f649a03aPharma Surgeen2026-07-29T12:04:18.000ZTeva Pharmaceutical Industries Releases Q2 2026 Financial Resultshttps://www.pharmaradar360.com/article/ai-accelerated-nonclinical-drug-testing-market-global-industry-analysis-and-oppo-75b61692d2b3209ePharma Surgeen2026-07-29T12:02:32.000ZAI-Accelerated Nonclinical Drug Testing Market : Global Industry Analysis and Opportunity Assessment, 2036https://www.pharmaradar360.com/article/3-biotech-stocks-with-massive-upside-to-buy-before-august-starts-ee43c1cc3a37dfbcPharma Surgeen2026-07-29T12:00:17.000Z3 Biotech Stocks With Massive Upside to Buy Before August Startshttps://www.pharmaradar360.com/article/azurion-systems-d225046c99d393bdPharma Surgeen2026-07-29T12:00:00.000ZAzurion Systemshttps://www.pharmaradar360.com/article/pharmather-collaborates-with-craft-health-to-evaluate-craftmake-tm-gmp-ready-pha-8f000be8835e2b36Pharma Surgeen2026-07-29T12:00:00.000ZPharmaTher Collaborates with Craft Health to Evaluate CraftMake(TM) GMP-Ready Pharmaceutical 3D Printing Platform for Personalized Peptideshttps://www.pharmaradar360.com/article/is-teva-pharmaceutical-industries-ltd-teva-facing-challenges-a-02afcb9600cae6b1Pharma Surgeen2026-07-29T11:52:22.000ZIs Teva Pharmaceutical Industries Ltd (TEVA) Facing Challenges Ahttps://www.pharmaradar360.com/article/pcsa-stock-jumps-as-traders-pile-into-biotech-micro-cap-11e328034abcbecbPharma Surgeen2026-07-29T11:47:00.000ZPCSA Stock Jumps As Traders Pile Into Biotech Micro-Caphttps://www.pharmaradar360.com/article/how-collegium-s-quarterly-beat-but-softer-outlook-could-reframe-collegium-pharma-0c42dc855dafb310Pharma Surgeen2026-07-29T11:45:14.000ZHow Collegium's Quarterly Beat but Softer Outlook Could Reframe Collegium Pharmaceutical (COLL) Investorshttps://www.pharmaradar360.com/article/v0281-fampridin-neuraxpharm-10mg-0891c61051503614Pharma Surgeen2026-07-29T11:43:55.000ZΑνάκληση της παρτίδας V0281, του φαρμακευτικού προϊόντος FAMPRIDIN-NEURAXPHARM 10MGhttps://www.pharmaradar360.com/article/teva-teva-pharmaceutical-expects-2026-adjusted-eps-range-1-91-2-11-e276dbb238db778fPharma Surgeen2026-07-29T11:39:41.000Z(TEVA) Teva Pharmaceutical Expects 2026 Adjusted EPS Range $1.91 - $2.11https://www.pharmaradar360.com/article/krystal-biotech-international-expansion-and-a-vibrant-pipeline-nasdaq-krys-12b5c2a3792a3252Pharma Surgeen2026-07-29T11:25:50.000ZKrystal Biotech: International Expansion And A Vibrant Pipeline (NASDAQ:KRYS)https://www.pharmaradar360.com/article/silexion-therapeutics-successfully-initiates-phase-2-3-clinical-trial-of-sil204-1ab84a942c01be07Pharma Surgeen2026-07-29T11:20:55.000ZSilexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Centerhttps://www.pharmaradar360.com/article/tscan-therapeutics-announces-first-patient-dosed-in-phase-3-alloha-2tm-a-pivotal-59a5851a6c7ceea8Pharma Surgeen2026-07-29T11:20:41.000ZTScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancieshttps://www.pharmaradar360.com/article/struggling-sarepta-therapeutics-appoints-former-abbvie-executive-as-savior-594538e5991bfa89Pharma Surgeen2026-07-29T11:14:37.000ZStruggling Sarepta Therapeutics appoints former AbbVie executive as saviorhttps://www.pharmaradar360.com/article/vaccination-coverage-statistics-england-cover-programme-april-2025-to-march-2026-01c427939f3cd7a6Pharma Surgeen2026-07-29T11:10:16.000ZVaccination coverage statistics, England (COVER programme): April 2025 to March 2026https://www.pharmaradar360.com/article/a-one-time-treatment-for-geographic-atrophy-gains-fda-rmat-status-95e47681f20823e0Pharma Surgeen2026-07-29T11:01:00.000ZA one-time treatment for geographic atrophy gains FDA RMAT statushttps://www.pharmaradar360.com/article/silexion-therapeutics-successfully-initiates-phase-2-3-be64b90a663d3264Pharma Surgeen2026-07-29T11:00:00.000ZSilexion Therapeutics Successfully Initiates Phase 2/3https://www.pharmaradar360.com/article/pbs-biotech-joins-organoid-commons-to-accelerate-industrialization-and-scalabili-f27a23a2b51fb292Pharma Surgeen2026-07-29T11:00:00.000ZPBS Biotech Joins Organoid COMMONS to Accelerate Industrialization and Scalability of Human-Relevant Modelshttps://www.pharmaradar360.com/article/survey-of-adult-carers-in-england-2025-to-2026-report-e8ab0027540dea50Pharma Surgeen2026-07-29T10:45:00.000ZSurvey of adult carers in England: 2025 to 2026 reporthttps://www.pharmaradar360.com/article/mutation-in-rice-protein-kinase-leads-to-drought-tolerance-b3df69e96ff2c468Pharma Surgeen2026-07-29T10:42:35.000ZMutation in Rice Protein Kinase Leads to Drought Tolerancehttps://www.pharmaradar360.com/article/ukhsa-spend-over-25-000-2026-a8b4b8d9bbff80c2Pharma Surgeen2026-07-29T10:39:15.000ZUKHSA spend over £25,000: 2026https://www.pharmaradar360.com/article/boston-scientific-announces-results-for-second-quarter-2026-d7bd1b5fc65d504fPharma Surgeen2026-07-29T10:30:00.000ZBoston Scientific announces results for second quarter 2026https://www.pharmaradar360.com/article/field-safety-notices-29-june-to-03-july-2026-baec98f35a228b98Pharma Surgeen2026-07-29T10:12:28.000ZField Safety Notices: 29 June to 03 July 2026https://www.pharmaradar360.com/article/legend-biotech-legn-stock-may-be-cheap-after-ceo-resignation-78c34c82bf2eff18Pharma Surgeen2026-07-29T10:08:12.000ZLegend Biotech (LEGN) Stock May Be Cheap After CEO Resignationhttps://www.pharmaradar360.com/article/june-m-a-recap-three-deals-three-billion-dollar-stories-02b7301895fa715fPharma Surgeen2026-07-29T10:06:54.000ZJune M&A recap: Three deals, three billion-dollar storieshttps://www.pharmaradar360.com/article/why-chinese-biotech-licensing-deals-became-attractive-to-us-investors-9ccbf2a2339710dcPharma Surgeen2026-07-29T10:04:53.000ZWhy Chinese Biotech Licensing Deals Became Attractive to US Investorshttps://www.pharmaradar360.com/article/respiratory-syncytial-virus-rsv-maternal-vaccination-coverage-in-england-march-2-30e801b2e4b499e7Pharma Surgeen2026-07-29T10:02:46.000ZRespiratory syncytial virus (RSV) maternal vaccination coverage in England: March 2026https://www.pharmaradar360.com/article/respiratory-syncytial-virus-rsv-older-adults-vaccination-coverage-in-england-jun-6e405552d2e63be0Pharma Surgeen2026-07-29T10:02:24.000ZRespiratory syncytial virus (RSV) older adults vaccination coverage in England: June 2026https://www.pharmaradar360.com/article/biotech-academy-gets-nearly-500k-for-boston-expansion-location-6b2ff9557e0a315aPharma Surgeen2026-07-29T10:00:00.000ZBiotech academy gets nearly $500k for Boston expansion locationhttps://www.pharmaradar360.com/article/zmiany-tak-ale-w-dialogu-i-likwidujace-bariery-cb528f4591811c94Pharma Surgeen2026-07-29T09:52:48.000ZZmiany tak, ale w dialogu i likwidujące barieryhttps://www.pharmaradar360.com/article/tasrif-pharmaceutical-announces-grant-of-second-u-s-patent-for-humanized-monoclo-048578436fdf4c11Pharma Surgeen2026-07-29T09:38:49.000ZTasrif Pharmaceutical Announces Grant of Second U.S. Patent for Humanized Monoclonal Antibodies Against the Poliovirus Receptor (CD155)https://www.pharmaradar360.com/article/krystal-biotech-profitable-self-funding-and-loaded-with-optionality-nasdaq-krys-0094231ae8befaefPharma Surgeen2026-07-29T09:33:01.000ZKrystal Biotech: Profitable, Self-Funding, And Loaded With Optionality (NASDAQ:KRYS)